Carlos H. Barrios

Research interests

Publications

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407086

• Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.11.016

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2202809

• Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.801

• Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2026982

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.355

• Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

  JNCI Journal of the National Cancer Institute · 2021 · https://doi.org/10.1093/jnci/djab004

• PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab -Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2021 · https://doi.org/10.1093/jnci/djab108

• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.02212

• Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917346

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)32531-9

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32591-7

• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30689-8

• Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1712126

• Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30717-9

• 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

  Annals of Oncology · 2016 · 10.1093/annonc/mdw544

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32517-x

• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)00986-1

• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds277

• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

  Annals of Oncology · 2011 · 10.1093/annonc/mdr435

• Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.1321

• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

  New England Journal of Medicine · 2005 · 10.1056/nejmoa052306

Current projects

No projects listed.